Genomics approaches ‘critical mass’ on data

Genomics approaches ‘critical mass’ on data

Little wonder that GlaxoSmithKline (GSK) has already come on board, investing $300m as part of a four-year collaborative venture with 23andMe. The pharma giant already has plans to study a potential …